These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1022316)

  • 1. Study of a microassay for the quantitation of cytotoxic antitumor antibody, using 125I-iododeoxyuridine as a target cell label; detection of a static effect on cell DNA synthesis.
    Le Mevel BP; Wells SA
    Biomedicine; 1976 Dec; 24(6):434-42. PubMed ID: 1022316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of cytotoxic antitumor antibody in vitro: a microassay with 125I-iododeoxyuridine as a tumor cell label.
    Fritze D; Kern DH; Pilch YH
    J Natl Cancer Inst; 1974 Nov; 53(5):1403-7. PubMed ID: 4431057
    [No Abstract]   [Full Text] [Related]  

  • 3. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells.
    Williams RM; Germain RN; Benacerraf B
    J Natl Cancer Inst; 1975 Mar; 54(3):697-708. PubMed ID: 1091740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibodies to the autologous tumor cells in tumor induction in mice using methylcholanthrene].
    Vetrova EP; Fedorovskaia MI; Kaminskaia LP; Umanskiĭ IuA
    Vopr Onkol; 1974; 20(3):59-62. PubMed ID: 4612978
    [No Abstract]   [Full Text] [Related]  

  • 5. A microassay for the guantitation of cytotoxic antitumor antibody: use of 125 I-iododeoxyuridine as a tumor cell label.
    LeMevel BP; Wells SA
    J Natl Cancer Inst; 1973 Mar; 50(3):803-6. PubMed ID: 4708159
    [No Abstract]   [Full Text] [Related]  

  • 6. Incorporation of 125-I-iododeoxyuridine into target cells as an assay for cell immunity.
    Fish F; Yaakubovicz M; Witz IP
    J Natl Cancer Inst; 1974 Dec; 53(6):1743-7. PubMed ID: 4436870
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro demonstration of complement-dependent cytotoxic antibodies to Moloney sarcoma cells.
    Tamerius JD; Hellström I
    J Immunol; 1974 Jun; 112(6):1987-96. PubMed ID: 4825783
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies.
    Dauphinee MJ; Talal N; Witz IP
    J Immunol; 1974 Sep; 113(3):948-53. PubMed ID: 4413555
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells.
    Oldham RK; Herberman RB
    J Immunol; 1973 Dec; 111(6):862-71. PubMed ID: 4750872
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody-induced killing in vivo of L1210/MTX-R cells quantitated in passively immunized mice with 131I-iododeoxyuridine-labeled cells and whole-body measurement of retained radioactivity.
    Carlson GA; Terres G
    J Immunol; 1976 Sep; 117(3):822-9. PubMed ID: 956654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of different doses of cyclophosphamide on the immune response of mice with a methylcholanthrene-induced sarcoma].
    Gordienko SP; Bergol'ts VM
    Vopr Onkol; 1973; 19(11):54-60. PubMed ID: 4785975
    [No Abstract]   [Full Text] [Related]  

  • 13. [Humoral immunity in human sarcomas].
    Sergeev SI; Bergol'ts VM; Kovalev BN; Timofeevskaia EA
    Vopr Onkol; 1976; 22(8):17-21. PubMed ID: 1069401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-mediated cytotoxicity: an assay using 125 I-iododeoxyuridine-labeled target cells.
    Cohen AM; Burdick JF; Ketcham AS
    J Immunol; 1971 Sep; 107(3):895-8. PubMed ID: 5572095
    [No Abstract]   [Full Text] [Related]  

  • 15. Spontaneous lytic activity against allogeneic tumor cells and depression of specific cytotoxic responses in mice infected with Trypanosoma cruzi.
    Hatcher FM; Kuhn RE
    J Immunol; 1981 Jun; 126(6):2436-42. PubMed ID: 6785354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum factors in mammary neoplasia: enhancement and antagonism of spleen cell activity in vitro detected by different methods of serum factor assay.
    Blair PB; Lane MA
    J Immunol; 1974 Feb; 112(2):439-53. PubMed ID: 4813898
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of lymphocytes and serum of C3Hf-Bu mice during the growth of methylcholanthrene-induced tumor and its regression following local irradiation.
    Jurin M; Suit HD
    Cancer Res; 1974 Apr; 34(4):672-8. PubMed ID: 4814987
    [No Abstract]   [Full Text] [Related]  

  • 18. Non T suppressor cells in the lymph nodes of mice bearing methylcholanthrene-induced sarcomas.
    Indrová M; Bubeník J
    Folia Biol (Praha); 1981; 27(3):217-22. PubMed ID: 6455309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative analysis of the sensitivity to natural killers and macrophages of 3-methylcholanthrene-induced tumors in mice].
    Viksler VKh; Iaroslavtseva OA; Lavroskiĭ VA
    Eksp Onkol; 1986; 8(6):36-40. PubMed ID: 3803287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.